Article Text

Download PDFPDF
Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa
  1. Gerald A Fishman,
  2. Marsha A Apushkin
  1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
  1. Correspondence to: Dr G A Fishman University of Illinois at Chicago Eye Center, University of Illinois at Chicago (M/C 648), 1855 W Taylor Street, Chicago, IL 60612, USA; gerafish{at}


Aim: To determine the value of a topical carbonic anhydrase inhibitor for extended treatment of cystoid macular oedema (CME) in patients with retinitis pigmentosa (RP).

Method: Eight patients with RP and foveal cystic-appearing lesions observed on fundus examination and by optical coherence tomography (OCT) testing were treated with a topical form of carbonic anhydrase inhibitor.

Results: Foveal cystic-like spaces were documented by OCT testing in all eight patients before treatment. All patients had a significant reduction in their foveal thickness (FT) and foveal zone thickness (FZT) in at least one eye after using 2% dorzolamide three times a day for 1 or 2 months. Six patients had an improvement in both eyes. After an additional 6–13 months of the same treatment regimen, out of six patients who had a sustained reduction in FT and FZT in at least one eye, four had this reduction in both eyes. While they were still taking Trusopt, a recurrence (rebound) of CME in both eyes was observed in two patients, whereas one patient had a sustained improvement in one eye and rebound of CME in the other eye. Out of 8 patients, 3 showed an improvement in their visual acuity by ⩾7 letters, in at least one eye, on Snellen acuity charts, which was determined as clinically significant.

Conclusion: Results from this study suggest that patients with RP could potentially sustain a beneficial effect from continued treatment with a topical form of carbonic anhydrase inhibitor.

  • BCVA, best-corrected visual acuity
  • CME, cystoid macular oedema
  • FT, foveal thickness
  • FZT, foveal zone thickness
  • OCT, optical coherence tomography
  • RP, retinitis pigmentosa

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 10 January 2007

  • Funding: This study was supported by funds from the Foundation Fighting Blindness, Owings Mills, Maryland; The Grant Healthcare Foundation, Chicago, Illinois; NEI core grant EY01792, Bethesda, Maryland; and an unrestricted departmental grant from Research to Prevent Blindness, New York, New York, USA.

  • Competing interests: None.

Linked Articles

  • BJO at a glance
    Creig Hoyt